Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Next-Generation Antibody Therapeutics Market is Expected to Grow at 21% CAGR During 2015 - 2020: P&S Market Research


News provided by

P&S Market Research

17 Aug, 2015, 14:30 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
P&S Market Research Logo (PRNewsFoto/P&S Market Research)

NEW YORK, August 17, 2015 /PRNewswire/ --

The global next-generation antibody therapeutics market was valued at $1,490.0 million in 2014 and it is expected to grow at a CAGR of 20.9% during the period 2015 - 2020. The global next-generation antibody therapeutics market is increasing due to growing global R&D activities. Various pharmaceutical and biotechnology companies are engaged in R&D for new improved next-generation antibody therapeutics, which would help in improved treatment of various chronic diseases, such as cancer, diabetes, cardiovascular diseases, infectious diseases and others. In addition, various pharmaceutical and biotechnology companies are involved in collaborations with other companies and organizations for the research and development of next-generation antibody therapeutics. Technological advancements in the field of next-generation antibody therapeutics are also driving the market. Recombinant technology has facilitated development of new and improved antibody therapeutics. Antibodies are genetically engineered to create smaller fragments of antibodies in order to increase their penetration into cancer cells. Such advancements in technology have resulted in the improved treatment options; and thus, are gaining popularity.

     (Logo: http://photos.prnewswire.com/prnh/20150727/756778)

Browse report description with detailed TOC on "Global Next-generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" at: https://www.psmarketresearch.com/market-analysis/next-generation-antibody-market

Based on therapeutic area, the autoimmune/inflammatory next-generation antibody therapeutics market is expected to witness the faster growth during the forecast period of 2015-2020. On the basis of technology, the next-generation antibody therapeutics market can be segmented as antibody-drug conjugates (ADCs), bispecific antibodies, Fc-engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. The biosimilar antibody products segment is expected to witness the fastest growth, CAGR of 22.5%, during the period 2015 - 2020.

The information and data in the publication "Global Next-generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" represent the research and analysis of data from various primary and secondary sources. Bottom-up approach has been used to calculate the global next-generation antibody therapeutics market by therapeutic area and technology. The market numbers for countries are obtained through top-down approach. P&S Market Research analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in this report. We base our primary research on discussions with prominent professionals and analysts in the industry, aided by informed and detailed online and offline research.

Browse more reports on Healthcare: https://www.psmarketresearch.com/industry-report/healthcare

Biosimilar antibody product refers to a copy of an already-authorized product, whose patent has expired. The cost of biosimilar antibody products being very low, as compared to the original antibody products, drives the demand of biosimilar antibody products market, specifically in low income regions and emerging markets of Asia-Pacific, Latin America, and Eastern Europe.

The increasing healthcare expenditure across the globe is encouraging consumers to use more number of next-generation antibody therapeutics to get improved treatment. Governments of various countries have been taking initiatives to provide improved healthcare facilities at affordable prices. In addition, another factor including growing prevalence of chronic diseases is driving the next-generation antibody therapeutics market at a significant rate. Next-generation antibody therapeutics provides improved treatment options for the treatment of chronic diseases, with minimum side effects.

However, certain restraints such as high cost of next-generation antibody therapeutics and strict regulatory requirements and long approval time for new drugs are hindering the market growth. Rural areas in the developing countries are emerging as a potential opportunity for the next-generation antibody therapeutics market.

The increasing healthcare expenditure and improving healthcare facilities in developing countries, such as China, India, and Brazil, are laying significant opportunity for next-generation antibody therapeutics market. North America next-generation antibody therapeutics market is expected to witness the fastest growth of CAGR 23.5% during the period 2015 - 2020. This is as a result of increasing number of chronic diseases cases, increasing healthcare expenditure, and rising R&D investments in the region. In addition, high adoption rate for improved healthcare facilities is boosting the market for next-generation antibody therapeutics market.

The key companies operating in the global next-generation antibody therapeutics market include Kyowa Hakko Kirin Co., Ltd., Dyax Corp., AstraZeneca plc, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer, Inc., Seattle Genetics, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals Company Limited, and Biogen.

NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SEGMENTATION 

Next-Generation Antibody Therapeutics Market by Therapeutic Area 

  • Oncology
  • Autoimmune/Inflammatory

Next-Generation Antibody Therapeutics Market by Technology 

  • Antibody-drug conjugates (ADCs)
  • Biosimilar antibody products
  • Antibody fragments and antibody-like proteins
  • Fc-engineered antibodies
  • Bispecific antibodies

GEOGRAPHICAL SEGMENTATION 

Next-Generation Antibody Therapeutics Market by Region 

  • North America
    • The U.S.
    • Rest of North America
  • Europe
    • Germany
    • The U.K.
    • France
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • Rest of the World (ROW)

Browse other reports: 

Global Bioinformatics Market - https://www.psmarketresearch.com/market-analysis/bioinformatics-market

Global Home Healthcare Market - https://www.psmarketresearch.com/market-analysis/home-healthcare-market

Global Medical Tourism Market - https://www.psmarketresearch.com/market-analysis/medical-tourism-market

Global Sterilization Equipment and Disinfectants Market - https://www.psmarketresearch.com/market-analysis/sterilization-equipment-and-disinfectants-market

About P&S Market Research 

P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication.  Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:
Ms Somya
Manager - Client Partner
347, 5th Ave. #1402
New York City, NY -10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.